Skip to content

Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section

Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04780412
Enrollment
210
Registered
2021-03-03
Start date
2020-09-01
Completion date
2021-03-31
Last updated
2021-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Respiratory Distress, Transient Tachypnea of the Newborn

Brief summary

Neonatal respiratory morbidities represent a common group of post natal complications including respiratory distress syndrome, transient tachypnea of newborn, and persistent pulmonary hypertension of newborn. It is thought that preoperative vaginal misoprostol administration may decrease the incidence of neonatal respiratory morbidity especially transient tachypnea of newborn. And therefore, it may decrease the incidence of admission to neonatal intensive care units for respiratory causes.

Interventions

DRUGMisoprostol

Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.

DRUGPlacebo

Vaginal placebo pills given 90-120 minutes before an elective caesarian section.

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age: 18 years or more. * Early term singleton pregnancy. * Elective caesarian section at (37 - 38+6) weeks of gestation. * Any indication for lower uterine segment caesarian section other than labor (as malpresentations, severe preeclampsia, placenta previa with no previous bleeding attacks, Diabetes Mellitus, macrosomic fetus, non reassuring cardiotocogram (CTG), and fetal growth restriction). * Informed written consent signed by the participating pregnant woman.

Exclusion criteria

* Women having any contraindication to Prostaglandin E1 as hypersensitivity, respiratory disease (especially bronchial asthma), or glaucoma. * Any mental problems that block understanding of the nature and all the possible consequences of the procedure and the study. * Pregnancies of known fetal diseases or chromosomal abnormalities. * Non-singleton pregnancies. * Emergency caesarian section as in ruptured membrane and women in labor pain.

Design outcomes

Primary

MeasureTime frameDescription
incidence of neonatal respiratory morbidity (NRM)up to 24 hours after birthThe incidence of neonatal respiratory morbidity, especially transient tachypnea of newborn, in early term neonates born to elective caesarian section.

Secondary

MeasureTime frameDescription
Neonatal intensive care unit (NICU) admissionup to 24 hours after birthThe incidence of the need for neonatal intensive care unit admission during the first ten days after delivery in early term neonates born to elective caesarian section.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026